Intriguingly, the genes that were downregulated in response to gilteritinib, also appear to be overexpressed and associated with poor prognosis in the EC, OC, and GC TCGA cohorts (CENPE, MCM4, GSPT1, MMS22L, DDX21, and VDAC1) that were components of the most enriched pathways, such as E2F and MYC, identified by GSEA. This evidence concerns the gene MCM4 and gastric cancer.